1H NMR DMSOD6
HR MS
1H NMR
/////////////
C1[C@H](S/C(=C(\C#N)/N2C=CN=C2)/S1)C3=C(C=C(C=C3)Cl)Cl
| Systematic (IUPAC) name | |
|---|---|
(2E)-[(4R)-4-(2,4-Dichlorophenyl)-1,3-dithiolan-2-ylidene](1H-imidazol-1-yl)acetonitrile
| |
| Clinical data | |
| Trade names | Luzu, Lulicon |
| Legal status |
|
| Routes of administration | Topical |
| Pharmacokinetic data | |
| Protein binding | >99%[1] |
| Identifiers | |
| CAS Number | 187164-19-8 |
| ATC code | D01AC18 |
| PubChem | CID 3003141 |
| ChemSpider | 2273807 |
| Chemical data | |
| Formula | C14H9Cl2N3S2 |
| Molar mass | 354.28 g/mol |
Luliconazole (trade names Luzu, Lulicon) is an imidazole antifungal drug. As a 1% topical cream, It is indicated for the treatment of athlete's foot, jock itch, and ringworm caused by dermatophytes such as Trichophyton rubrum, Microsporum gypseum[2] andEpidermophyton floccosum.[1]
References
- ^ a b "LUZU (luliconazole) Cream, 1%. Full Prescribing Information." (PDF). Valeant Pharmaceuticals North America LLC. Retrieved1 October 2015.
- ^ "FDA approves luliconazole for tinea pedis". November 19, 2013. Retrieved 14 January 2014.
External links
HR MS
1H NMR
/////////////
C1[C@H](S/C(=C(\C#N)/N2C=CN=C2)/S1)C3=C(C=C(C=C3)Cl)Cl


